在使用抗精神病药物进行长期治疗时加用卡马西平可能会诱发抗精神病药物恶性综合征。
Addition of carbamazepine to long-term treatment with neuroleptics may induce neuroleptic malignant syndrome.
作者信息
Nisijima K, Kusakabe Y, Ohtuka K, Ishiguro T
机构信息
Department of Psychiatry, Jichi Medical School, Tochigi-Ken, Japan.
出版信息
Biol Psychiatry. 1998 Nov 1;44(9):930-1. doi: 10.1016/s0006-3223(98)00025-0.
BACKGROUND
Carbamazepine is an anticonvulsant, but also has an anti-manic effect, and recently it has been increasingly used in combination with neuroleptics. Nevertheless, there have been very few reports on the involvement of carbamazepine in the occurrence of neuroleptic malignant syndrome (NMS).
METHODS
A case of NMS occurring after addition of carbamazepine to long-term neuroleptic administration is described.
RESULTS
The patient had been treated with neuroleptics for about 30 years, and NMS developed when carbamazepine (400 mg/day) was added.
CONCLUSIONS
This case suggests that clinicians should consider the risk of NMS when carbamazepine is administered to patients undergoing long-term treatment with neuroleptics.
背景
卡马西平是一种抗惊厥药，但也具有抗躁狂作用，最近它越来越多地与抗精神病药物联合使用。然而，关于卡马西平与抗精神病药物恶性综合征（NMS）发生之间关联的报道非常少。
方法
描述了1例在长期服用抗精神病药物基础上加用卡马西平后发生NMS的病例。
结果
该患者接受抗精神病药物治疗约30年，加用卡马西平（400毫克/天）后发生了NMS。
结论
该病例提示，临床医生在给长期接受抗精神病药物治疗的患者使用卡马西平时应考虑发生NMS的风险。
Zotero 插件